Here are 1-2 brief analogies to describe Spero Therapeutics (SPRO):

• Spero Therapeutics is like Gilead Sciences, but focused on developing new antibiotics for drug-resistant bacterial infections instead of antivirals for diseases like HIV or Hepatitis C.
• Think of Spero as a 'startup' version of a big pharmaceutical company like Merck or Pfizer, but singularly dedicated to finding treatments for 'superbugs' (multi-drug resistant bacteria).

• Tebipenem Pivoxil Hydrobromide (HBr): An oral carbapenem-class antibiotic designed to treat complicated urinary tract infections, including pyelonephritis for adults.
• SPR206: A direct-acting, IV-administered agent developed to treat multi-drug resistant Gram-negative bacterial infections in a hospital setting.
• SPR720: An oral antibiotic intended for the treatment of non-tuberculous mycobacterial pulmonary disease.

Spero Therapeutics (SPRO) is a clinical-stage biopharmaceutical company. As such, it does not currently sell approved commercial products directly to individuals or healthcare providers. Instead, its revenue streams primarily come from licensing agreements, collaboration agreements, and development support from other companies and institutions for its product candidates and intellectual property.

Based on the provided information, Spero Therapeutics' major customers are other companies and institutions that partner with or license technology from Spero. These include:

• Everest Medicines (1952.HK)
• Bill & Melinda Gates Medical Research Institute
• Vertex Pharmaceuticals Incorporated (VRTX)
• Meiji Seika Pharma Co., Ltd. (a subsidiary of Meiji Holdings Co., Ltd., 2269.T)

• Meiji Seika Pharma Co., Ltd.
• Vertex Pharmaceuticals Incorporated (VRTX)

Esther Rajavelu, President, Chief Executive Officer, Chief Financial Officer, and Treasurer

Esther Rajavelu was appointed President and Chief Executive Officer of Spero Therapeutics, effective May 2, 2025, and continues to serve as Chief Financial Officer and Treasurer. She has over two decades of experience in the life sciences sector, encompassing equities research, investment banking, and strategy consulting. Before joining Spero, Ms. Rajavelu served as CFO at Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, where she led equity financings and developed strategic plans to optimize capital deployment. Her career on Wall Street included roles as a senior equities research analyst at UBS, Oppenheimer, and Deutsche Bank, and a healthcare investment banker at Bank of America Merrill Lynch and EY Capital Advisors.

Timothy Keutzer, Chief Operating Officer

Timothy Keutzer serves as the Chief Operating Officer at Spero Therapeutics, bringing over 30 years of experience in the pharmaceutical industry across various functional and therapeutic areas. Prior to his current role, he was Spero's Chief Development Officer. Before joining Spero, Mr. Keutzer was the Vice President of Program and Portfolio Management at Cubist Pharmaceuticals, where he notably led the program for ceftolozane/tazobactam from Phase 1 to Phase 3, leading to its U.S. approval in December 2014.

Kamal Hamed, Chief Medical Officer

Kamal Hamed is the Chief Medical Officer at Spero Therapeutics, a position he has held since 2022. He possesses over 20 years of experience in leading anti-infective clinical development programs for antibacterials, antivirals, antimalarials, and antifungals. His prior roles include serving as CMO at Lysovant Sciences, a subsidiary of Roivant Sciences, and as Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica. Dr. Hamed also held senior positions in clinical development and medical affairs at Novartis, Bristol-Myers Squibb, and Bayer.

John Raymond, Senior Vice President of Finance and Business Operations

John Raymond is the Senior Vice President of Finance and Business Operations at Spero Therapeutics. He has more than 25 years of experience in the life sciences sector, specializing in financial management, strategic planning and analysis, and commercial/business operations. Before joining Spero, Mr. Raymond held roles of increasing responsibility at companies such as Abbott Laboratories, Cubist Pharmaceuticals, Genzyme/Sanofi, and ImmunoGen.

The key risks to Spero Therapeutics (SPRO) primarily revolve around the inherent challenges of biopharmaceutical development and commercialization, especially given its focus on multi-drug resistant bacterial infections.

• Regulatory Approval and Commercialization of Tebipenem HBr: Despite positive Phase 3 results for tebipenem HBr in complicated urinary tract infections (cUTI) and its resubmission by partner GSK for FDA approval, there remains a significant risk regarding the ultimate regulatory decision. Spero Therapeutics previously faced a complete response letter (CRL) from the FDA for tebipenem HBr, and though a new pivotal Phase 3 trial (PIVOT-PO) demonstrated efficacy, final approval is not guaranteed. The company's financial future, including potential milestone payments and royalties, is heavily dependent on GSK successfully navigating the regulatory pathway and achieving commercial success for this lead product candidate.
• Pipeline Concentration and Clinical Development Risk: Spero Therapeutics recently suspended the development of SPR720, an oral antibiotic for non-tuberculous mycobacterial pulmonary disease, after it failed to meet its primary endpoint in a Phase 2a study and showed potential dose-limiting safety issues. This significant setback highlights the high attrition rate inherent in drug development and leaves the company's pipeline heavily reliant on the success of tebipenem HBr. The remaining clinical candidate, SPR206, is in earlier stages, with its Phase 2 trial contingent on continued non-dilutive funding, further emphasizing the concentration of risk on their lead asset.
• Capital Requirements and Funding Dependence: As a clinical-stage biopharmaceutical company, Spero Therapeutics faces ongoing significant capital demands for its research and development activities. While the company has extended its cash runway into 2028 through a partnership with GSK and workforce reductions following the SPR720 failure, its financial stability remains largely dependent on the successful regulatory approval and commercialization of tebipenem HBr, which would trigger milestone payments and royalties. Any delays or negative outcomes for tebipenem HBr could impact these expected funds, potentially necessitating further capital raises through dilutive financing or additional restructuring.

Spero Therapeutics (SPRO) operates in markets addressing serious bacterial infections and rare diseases. The addressable markets for its main product candidates are as follows:

• Tebipenem pivoxil hydrobromide (HBr) for complicated urinary tract infections (cUTI), including pyelonephritis: The addressable market for tebipenem HBr is significant. Spero Therapeutics has estimated the total addressable market at approximately 2.9 million annual cUTI treatment episodes in the United States alone. These cases contribute to more than $6 billion in US healthcare costs. Other reports suggest the complicated urinary tract infection treatment market globally was valued at $9.44 billion in 2025 and is projected to reach $12.74 billion by 2030. The 7 major complicated urinary tract infections (cUTIs) market, including the US, EU4, UK, and Japan, was valued at approximately USD 1,375 million in 2025 and is projected to reach USD 2,259 million by 2034. The United States accounted for approximately 57% of the total 7MM cUTI market share in 2024.
• SPR206 for multi-drug resistant (MDR) Gram-negative bacterial infections in the hospital: The global hospital-treated Gram-negative infections market was valued at USD 10.87 billion in 2025 and is expected to reach USD 22.10 billion by 2033. North America held the largest revenue share, accounting for 37.2% of this market in 2025. Separately, the global multidrug resistant bacteria market size was valued at USD 12.19 billion in 2024 and is projected to reach USD 18.85 billion by 2032.
• SPR720 for non-tuberculous mycobacterial (NTM) pulmonary disease: The global Nontuberculous Mycobacterium Treatment Market size was valued at USD 9.8 billion in 2025 and is projected to reach USD 12.8 billion by the end of 2035. North America is anticipated to be the largest region, holding a 39% share by 2035, and is also projected to be the fastest-growing region. In the United States specifically, the total Nontuberculous Mycobacterial Treatment Market was approximately USD 360 million in 2023.

Spero Therapeutics (SPRO), a clinical-stage biopharmaceutical company, is anticipated to drive future revenue growth over the next two to three years primarily through the advancement and potential commercialization of its lead product candidate, tebipenem HBr, and through development milestones from its partnership for SPR206.

Here are 3-5 expected drivers of future revenue growth:

1. Tebipenem HBr Regulatory Approval and Initial Commercialization: The successful Phase 3 PIVOT-PO trial for tebipenem HBr, an oral carbapenem for complicated urinary tract infections (cUTI), met its primary endpoint, leading to an early halt of the trial for efficacy in May 2025. Spero's development partner, GSK, plans to submit the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025, with a regulatory decision anticipated in the second half of 2026. If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the U.S., offering a significant alternative to intravenous therapies for cUTI, potentially reducing hospital stays. This approval and subsequent commercial launch by GSK are expected to generate royalties on net sales for Spero.
2. Tebipenem HBr Milestone Payments from GSK: Beyond potential royalties from commercialization, Spero is eligible to receive significant milestone payments from GSK. An initial $25 million milestone payment is expected in the first quarter of 2026 upon GSK's NDA submission for tebipenem HBr. Additionally, Spero could qualify for up to $351 million in further contingent milestones based on commercialization and sales ramp as outlined in the licensing agreement with GSK.
3. SPR206 Development Milestones from Pfizer Partnership: Spero's other product candidate, SPR206, an IV-administered agent for multi-drug resistant (MDR) Gram-negative bacterial infections, is progressing. In February 2024, Spero received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 2 clinical study for SPR206. This Phase 2 study will evaluate SPR206 in combination with other antibiotics for hospital-acquired or ventilator-associated bacterial pneumonia. Spero has a licensing agreement with Pfizer Inc., granting Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories. Spero is eligible to receive up to $80 million in development and sales milestones, along with tiered royalties on net sales in these territories, as the program advances through clinical development.

Share Issuance

• In June 2021, Pfizer Inc. made a $40 million equity investment, purchasing 2,362,348 shares of Spero Therapeutics' common stock at $16.93 per share.
• In November 2022, GSK invested $9 million in Spero's common stock by purchasing 7,450,000 shares at approximately $1.21 per share.
• Spero Therapeutics had net proceeds of $14.2 million from the sale of common stock under an "at-the-market" offering program in 2022.

Inbound Investments

• In June 2021, Spero Therapeutics received a $40 million equity investment from Pfizer Inc. and entered into a licensing agreement for SPR206, which included potential development and sales milestones of up to $80 million and royalties.
• In September 2022, Spero Therapeutics entered an exclusive license agreement with GSK for tebipenem HBr, receiving an upfront payment of $66 million and eligibility for up to $525 million in development, sales, and commercial milestones, along with tiered royalties.
• Spero Therapeutics qualified for $95 million in development milestones from GSK for the PIVOT-PO clinical trial, payable in four equal installments, with the final $23.8 million payment received in August 2025.

Capital Expenditures

• Spero Therapeutics expects its existing cash and cash equivalents, along with non-dilutive funding commitments, to fund operating expenses and capital expenditures into 2028, as reported in Q2 and Q3 2025.
• Capital expenditures are primarily focused on funding research and development activities for the company's clinical programs, notably the Phase 3 PIVOT-PO trial for tebipenem HBr.
• A strategic restructuring in October 2024, which included a reduction in force and the suspension of SPR720 development plans, aimed to streamline operations and extend the company's cash runway.